Global Liquid Biopsy Market Size & Forecast 2026–2034
Introduction: A New Era in Cancer Diagnostics
The global healthcare landscape is undergoing a profound transformation, driven by the convergence of biotechnology, genomics, and data-driven medicine. Among the most promising advancements in modern oncology is liquid biopsy—a minimally invasive diagnostic approach that is redefining how cancer is detected, monitored, and treated. Unlike conventional tissue biopsies, liquid biopsy relies on analyzing biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other nucleic acids found in body fluids, primarily blood.
Comments
There are no comments for this story
Be the first to respond and start the conversation.